EssilorLuxottica acquires Canadian startup Cellview Imaging
Toronto-based Cellview currently designs and manufactures highly performant diagnostic imaging instruments that leverage internal R&D expertise, according to a news release.
Image credit: AdobeStock/Panumas
EssilorLuxottica has announced its acquisition of Cellview Imaging, a Canadian startup specializing in innovative diagnostic via retinal imaging.1 By joining forces, the companies will plan on building a wider portfolio of ophthalmic instruments and solutions within the med-tech space, according to a news release.
“We are happy to welcome Cellview’s team to EssilorLuxottica and to work together to accelerate our strategy in vision health,” said a joint statement from Francesco Milleri, chairman and CEO, and Paul du Saillant, deputy CEO, of EssilorLuxottica, in the release. “By integrating another pioneering company with strong expertise in R&D and world class imaging solutions, we will provide a comprehensive portfolio of innovative technologies to the ophthalmic care community to better address the growing need of vision health and the early diagnosis of retinal pathologies. While our products and services remain accessible to all industry players – as a pillar of EssilorLuxottica’s open business model – we continue to elevate market standards, in full alignment with our journey into the med-tech space.”
Toronto-based Cellview currently designs and manufactures highly performant diagnostic imaging instruments that leverage internal R&D expertise, which are distributed in North America.1 The company’s device, WRI-1,2 allows eye care providers to diagnose retinal pathologies with an ultra-widefield retinal camera that captures larger images compared to most devices on the market, according to the release. The diagnostic tool produces an image up to 133 degrees in a single capture, or 200 degrees in an automated 2 image auto-stitched. WRI-1 penetrates to the deepest layers of the eye through cataracts, small pupils, and other media opacities.2
Cellview’s product offering is FDA and CE approved, with a market base ranging from eye care practices, retail locations, and ophthalmology clinics. Cellview is looking to broaden its distribution to different geographies, starting with Europe.1
References:
EssilorLuxottica acquires the Candian med-tech startup Cellview. News release. EssilorLuxottica. February 11, 2025. Accessed February 11, 2025.
Welcome to the future of retinal imaging. Cellview Imaging. Accessed February 11, 2025. https://cellviewimaging.com/en-us
